Skip to main content

Lila Sciences

Category: AI Infrastructure

Lila Sciences is developing a scientific superintelligence platform with fully autonomous labs (AI Science Factories) to accelerate discovery in life, chemical, and materials sciences. Lila Sciences was founded in 2023. The company is led by Geoffrey von Maltzahn. Based in Cambridge, USA. Team size: 150-200. Total funding raised: $550 million. Latest round: Series A extension. Key investors include ["Flagship Pioneering","Braidwell","Collective Global","NVentures (NVIDIA)","General Catalyst","ARK Venture Fund","In-Q-Tel","Analog Devices","March Capital","Altitude Life Science Ventures"].

Founded
2023
Headquarters
Cambridge, USA
Team size
150-200
Total funding
$550 million

Value proposition

To reinvent the scientific method by making it faster, cheaper, and smarter through the integration of AI and robotics, enabling rapid design, testing, and analysis of new scientific concepts at scale beyond human capacity

Products and solutions

["Scientific Superintelligence Platform","AI Science Factories (Autonomous Labs)","AI-driven discovery tools for life sciences, chemical sciences, and materials sciences","End-to-end autonomous experimentation pipeline"]

Unique value

Lila Sciences' uniqueness lies in its integrated platform that combines a 'scientific superintelligence' with fully autonomous, robotic laboratories (AI Science Factories). This creates a closed-loop system where AI can design experiments and robots execute them, enabling massive scale scientific discovery beyond human limitations.

Target customer

Enterprises in R&D-intensive industries such as pharmaceuticals, energy, semiconductors, materials science, and biotechnology

Industries served

["Life Sciences","Chemical Sciences","Materials Sciences","Pharmaceuticals","Energy","Semiconductors","Biotechnology","Green Technology"]

Technology advantage

The company's primary advantage is dramatically accelerating the cycle of scientific discovery by automating the entire process from hypothesis to experimentation and analysis. Their platform can tackle complex scientific challenges intractable with traditional methods, operating 24/7 with superhuman speed and accuracy.

How they differentiate

Lila AI differentiates itself by creating a closed-loop, end-to-end platform that combines proprietary AI 'superintelligence' with fully autonomous, robotic wet labs. Unlike competitors focused on drug discovery alone, Lila operates across life sciences, chemistry, and materials science, providing infrastructure as an 'AWS for science'.

Main competitors

["Recursion Pharmaceuticals","Schrödinger","Ginkgo Bioworks","Atomwise","Exscientia"]

Key partnerships

["NVentures (NVIDIA's venture arm)","Flagship Pioneering","AWS (Amazon Web Services)","In-Q-Tel (CIA's venture fund)","Analog Devices","Major pharmaceutical and energy companies (in development)"]

Notable customers

["Information not publicly available - company is in early customer onboarding phase"]

Major milestones

["Launched in March 2025 with $200 million seed round from Flagship Pioneering","Secured total of $550 million in funding","Reached valuation of over $1.3 billion in October 2025","Discovered and validated hundreds of novel antibodies and peptides using platform","Developed novel, non-platinum group metal catalyst for green hydrogen production","Established AI-powered autonomous lab facility in Cambridge, MA","Signed 235,500-square-foot Cambridge lab lease for expansion","Completed $350M Series A round with NVIDIA backing"]

Growth metrics

Achieved $1.3+ billion valuation within 2 years of founding. Discovered and validated hundreds of novel antibodies and peptides. Developed novel non-platinum group metal catalyst for green hydrogen production. Rapidly scaling from ~25 to 150+ employees with plans to double headcount.

Market positioning

Lila AI positions itself as a foundational 'platform of platforms' for scientific discovery, providing underlying infrastructure (AI and automated labs) to tackle wide-ranging scientific challenges rather than focusing on single therapeutic areas.

Geographic focus

Headquartered in Cambridge, Massachusetts, with expansion to multiple global locations including Boston, London, and San Francisco. Initial focus on North American market with international expansion planned.

Patents and IP

Information regarding specific patents or IP is not publicly available at this time, though the company claims proprietary technology in scientific superintelligence and autonomous lab integration.

About Geoffrey von Maltzahn

General Partner at Flagship Pioneering, where he has co-founded numerous life sciences and biotechnology companies, including Tessera Therapeutics and Sana Biotechnology. Currently serves as CEO and board member of Lila Sciences, board chair of Tessera Therapeutics, and chief innovation officer of Indigo Agriculture.

Official website: